Intelligence » Diabetes » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Gestational diabetes linked to ADHD in children: Study suggests the need for addressing metabolic health before conception

Monday, December 11, 2017 -- (Natural News) Mothers who develop diabetes during their pregnancy — a condition that is known as gestational diabetes (GDM) — have an increased likelihood of having a child who will display attention deficit hyperactivity disorder (ADHD) symptoms as early as six to 18 months of age. This is the warning researchers from the A*STAR Singapore... Read More

Can a Cocoa Compound Delay Diabetes?

Wednesday, December 13, 2017 -- By Dr. Mercola According to the American Diabetes Association,1 more than 30 million Americans are living with diabetes, the majority of whom are Type 2 diabetics. Another 84 million Americans have prediabetes, meaning they could advance to the full-blown disease in less than five years. By 2035, diabetes is expected to afflict 592 million people globally.2 As I have often said, a healthy lifestyle not only can prevent Type 2 diabetes, but is also capable of reversing it. With proper attention to diet and lifestyle, Type 2 diabetes is, in most cases, a curable condition. In the majority of situations, it does not require medication. Based on its influence on blood glucose levels, research has suggested a compound found

Diabetes Treatments of the Future: Insulin-Producing Cell Implants

Saturday, December 09, 2017 -- A new approach to regenerating insulin production in people with type 1 diabetes is gaining steam in California. An alternative to the often-discussed technological improvements leading to a closed loop insulin delivery system, the insulin-producing cell implants are a biological solution to the issue of non-insulin producing pancreases (a challenge we know as type 1 […]

Can Diabetes Cause Muscle Cramps?

Sunday, December 10, 2017 -- A recent study looked at links between muscle cramp frequency and severity and nerve fiber measures in patients with type 1 and type 2 diabetes. Persons with type 1 and 2 diabetes as well as healthy controls were given an evaluation and their large and small nerve fibers were assessed. Details about their muscle cramps […]

Diabetes drug manufacturers unable to prove any real benefit to patients

Sunday, December 10, 2017 -- (Natural News) Manufacturers of diabetes drugs could not prove any real additional benefit of sitagliptin to individuals with diabetes, according to a report by the Institute for Quality and Efficiency in Health Care (IQWiG). The IQWiG reevaluated the effects of the diabetes drug known as sitagliptin compared to the appropriate comparator therapies for diabetic people.... Read More

University of Wollongong launches 3D bioprinter to combat diabetes

Monday, December 11, 2017 -- A Pancreatic Islet Cell Transplantation (PICT) 3D bio-printer has been developed by researchers from the University of Wollongong’s ARC Centre of Excellence for Electromaterials Science (ACES) and will be used to treat diabetes at the Royal Adelaide Hospital (RAH) in Australia. The bio-printer, which is capable of producing pancreatic islets suitable for transplantation to diabetes sufferers […]

FDA Approves New Once-Weekly Ozempic for Type 2 Diabetes

Monday, December 11, 2017 -- The FDA has approved Novo Nordisk’s new type 2 diabetes drug–the once-weekly semaglutide, marketed as Ozempic. Ozempic, which is part of a diabetes class of drugs called GLP-1 (glucagon peptide receptor agonist), lowers blood sugar by boosting insulin secretion. The FDA approved semaglutide for adults with type 2 diabetes based on results from the Phase […]

FDA Gives Final OK to First Short-Acting Follow-On Insulin for Diabetes

Monday, December 11, 2017 -- Officials with the FDA today approved insulin lispro injection (Admelog, Sanofi-Aventis US) 100 units/mL, the first short-acting insulin approved as a follow-on product.

FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

Monday, December 11, 2017 -- (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

3D Bioprinter Offers New Treatment for Type 1 Diabetes

Tuesday, December 12, 2017 -- Researchers at the University of Wollongong have done some impressive things. They’ve 3D printed brain tissue, and developed a 3D printing pen capable of drawing cartilage into knees.... View the entire article via our website.

FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer

Monday, December 11, 2017 -- [12-12-2016] As a result of an updated review, the U.S. Food and Drug Administration (FDA) has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer.

FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin

Monday, December 11, 2017 -- [4-5-2016] A U.S. Food and Drug Administration (FDA) safety review has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease.

Is Diabetes Associated with Higher Cancer Incidence?

Tuesday, December 12, 2017 -- Diabetes is a common metabolic disorder. Researchers recently examined if diabetes is also associated with higher cancer incidence. Diabetes is a metabolic disorder that is estimated to affect 7% of Canadians (approximately 2.1 million) according to Statistics Canada. Diabetics suffer from uncontrolled blood glucose levels due to complications releasing insulin, a blood glucose regulating hormone. […] The post Is Diabetes Associated with Higher Cancer Incidence? appeared first on Medical News Bulletin | Health News and Medical Research.

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections

Monday, December 11, 2017 -- A U.S. Food and Drug Administration (FDA) safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization.

What is the Most Effective Strategy for Diabetes Prevention?

Thursday, December 14, 2017 -- Researchers recently investigated the long-term effectiveness of diabetes prevention approaches on the incidence of diabetes-related mortality and morbidity. Currently, diabetes affects over 415 million adults worldwide and this is expected to increase to as many as 642 million adults by the year 2040. Since diabetes treatment cost the US healthcare system over $245 billion in […] The post What is the Most Effective Strategy for Diabetes Prevention? appeared first on Medical News Bulletin | Health News and Medical Research.

Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes

Monday, December 11, 2017 -- Researchers at Lund University in Sweden have found that the presence of death receptors in the blood can be used to directly measure the risk of developing cardiovascular diseases and type 2 diabetes.

Identification of GAD65 AA 114-122 reactive 'memory-like' NK cells in newly diagnosed Type 1 diabetic patients by HLA-class I pentamers

Wednesday, December 13, 2017 -- by Valentina Perri, Elena Gianchecchi, Loredana Cifaldi, Marsha Pellegrino, Ezio Giorda, Marco Andreani, Marco Cappa, Alessandra Fierabracci Type 1 diabetes is an autoimmune disease, in which pancreatic β cells are destroyed by autoreactive T cells in genetically predisposed individuals. Serum beta cell autoantibody specificities have represented the mainstay for classifying diabetes as autoimmune-mediated and for stratifying risk in first-degree relatives. In recent years, approaches were attempted to solve the difficult issue of detecting rare antigen-specific autoreactive T cells and their significance to etiopathogenesis such as the use of the MHC multimer technology. This tool allowed the specific detection of increased percentages of GAD65 autoreactive T cells by means of HLA A*02:01 GAD65 AA 114–122 pentamers in newly diagnosed diabetics.

Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy

Thursday, December 14, 2017 -- by Keitaro Hase, Atsuhiro Kanda, Ikuyo Hirose, Kousuke Noda, Susumu Ishida (Pro)renin receptor [(P)RR], a new component of the tissue renin-angiotensin system (RAS), plays a crucial role in inflammation and angiogenesis in the eye, thus contributing to the development of proliferative diabetic retinopathy (PDR). In this study, we investigated systemic factors related to plasma levels of soluble form of (P)RR [s(P)RR] in patients with PDR. Twenty type II diabetic patients with PDR and 20 age-matched, non-diabetic patients with idiopathic macular diseases were enrolled, and plasma levels of various molecules were measured by enzyme-linked immunosorbent assays. Human retinal microvascular endothelial cells were stimulated with several diabetes-related conditions to evaluate changes in gene expression using real-time quantitative PCR. Of various systemic

Tumor necrosis factor-α antagonist diminishes osteocytic RANKL and sclerostin expression in diabetes rats with periodontitis

Thursday, December 14, 2017 -- by Ji-Hye Kim, Ae Ri Kim, Yun Hui Choi, Sungil Jang, Gye-Hyeong Woo, Jeong-Heon Cha, Eun-Jung Bak, Yun-Jung Yoo Type 1 diabetes with periodontitis shows elevated TNF-α expression. Tumor necrosis factor (TNF)-α stimulates the expression of receptor activator of nuclear factor-κB ligand (RANKL) and sclerostin. The objective of this study was to determine the effect of TNF-α expression of osteocytic RANKL and sclerostin in type 1 diabetes rats with periodontitis using infliximab (IFX), a TNF-α antagonist. Rats were divided into two timepoint groups: day 3 and day 20. Each timepoint group was then divided into four subgroups: 1) control (C, n = 6 for each time point); 2) periodontitis (P, n = 6 for each time point); 3) diabetes

UAE- Diabetes can increase risk of depression

Saturday, December 09, 2017 -- (MENAFN - Khaleej Times) Living with diabetes can be overwhelming at times. With the myriad problems that diabetes brings, it also brings an increased risk of depression. Hence, a ...